Cardillo TM - Search Results

1

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.

Cardillo TM, Zalath MB, Arrojo R, Sharkey RM, Govindan SV, Chang CH, Goldenberg DM. Cardillo TM, et al. Oncotarget. 2024 Feb 22;15:144-158. doi: 10.18632/oncotarget.28559. Oncotarget. 2024. PMID: 38386805 Free PMC article.

2

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Goldenberg DM, et al. Among authors: cardillo tm. Oncotarget. 2015 Sep 8;6(26):22496-512. doi: 10.18632/oncotarget.4318. Oncotarget. 2015. PMID: 26101915 Free PMC article.

3

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Goldenberg DM, et al. Among authors: cardillo tm. Oncotarget. 2020 Mar 10;11(10):942. doi: 10.18632/oncotarget.27512. eCollection 2020 Mar 10. Oncotarget. 2020. PMID: 32206190 Free PMC article.

4

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.

Cardillo TM, Rossi DL, Zalath MB, Liu D, Arrojo R, Sharkey RM, Chang CH, Goldenberg DM. Cardillo TM, et al. Oncotarget. 2020 Oct 27;11(43):3849-3862. doi: 10.18632/oncotarget.27766. eCollection 2020 Oct 27. Oncotarget. 2020. PMID: 33196706 Free PMC article.

5

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Cardillo TM, et al. Clin Cancer Res. 2011 May 15;17(10):3157-69. doi: 10.1158/1078-0432.CCR-10-2939. Epub 2011 Mar 3. Clin Cancer Res. 2011. PMID: 21372224 Free PMC article.

6

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Govindan SV, et al. Among authors: cardillo tm. Mol Cancer Ther. 2013 Jun;12(6):968-78. doi: 10.1158/1535-7163.MCT-12-1170. Epub 2013 Feb 20. Mol Cancer Ther. 2013. PMID: 23427296

7

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.

Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH. Cardillo TM, et al. BMC Cancer. 2013 Apr 1;13:170. doi: 10.1186/1471-2407-13-170. BMC Cancer. 2013. PMID: 23548153 Free PMC article.

8

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer.

Liu D, Cardillo TM, Wang Y, Rossi EA, Goldenberg DM, Chang CH. Liu D, et al. Among authors: cardillo tm. Mol Cancer. 2014 Mar 10;13:53. doi: 10.1186/1476-4598-13-53. Mol Cancer. 2014. PMID: 24606732 Free PMC article.

9

Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM. Govindan SV, et al. Among authors: cardillo tm. Mol Pharm. 2015 Jun 1;12(6):1836-47. doi: 10.1021/mp5006195. Epub 2014 Nov 25. Mol Pharm. 2015. PMID: 25402018 Clinical Trial.

10

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Cardillo TM, et al. Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8. Bioconjug Chem. 2015. PMID: 25915780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page